This open access book builds on and updates work performed in the HYBRIDA project, funded by the EU to develop an ethical framework for organoid research. Organoids are three-dimensional stem cell constructs that mimic organs of the body or tumours. Patient-derived organoids are envisioned to be grown from individual patients' tumours and used to tailor the most effective and safest treatments in a new form of personalized medicine. This text offers a critical assessment of this vision from the perspective of philosophy of medicine. The authors present a tailored vision assessment, presented as examples of methodological development, and applied to objects. They first analyse and describe the vision of using organoids for personalized cancer medicine, then critically evaluate this vision and finally comment on ethical implications of the epistemological issues and how to handle them. The authors further draw on sources for empirical inquiries. This book presents an exercise in health technology assessment conducted by philosophers. Its core readership are philosophers of medicine and bioethicists interested in personalized medicine and stem cell research.

Addresses emerging technology with significant implications for medical research and practice Shows how visions and emerging technology can be assessed systematically Provides the first comprehensive review of the field of patient-derived organoids for cancer This book is open access, which means that you have free and unlimited access

Autorentext

Henrik Vogt and Maxence Gaillard both work at the Center for Medical Ethics, University of Oslo, Norway.

Sara Green is affiliated with the Department of Science Education, University of Copenhagen, Denmark. She is an Associate Professor at the Section for History and Philosophy of Science.

Klappentext

Introduction.- Methodological development.- Vision analysis of patient-derived organoids for personalized cancer medicine.- Vision evaluation of patient-derived organoids in the clinic.- Conclusion.

Inhalt

Introduction.- Methodological development.- Vision analysis of patient-derived organoids for personalized cancer medicine.- Vision evaluation of patient-derived organoids in the clinic.- Conclusion.